AZD-4017 Drug Asset Due Diligence Report 2026

This AZD-4017 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether AZD-4017 can convert its Small molecule drug profile and 11β-HSD1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	AZD-4017 (query alias: AZD-4017)
Modality / target	Small molecule drug; 11β-HSD1; 11β-HSD1 inhibitors
Highest global status	Phase 2
Originator	AstraZeneca PLC
Active developers	AstraZeneca Pharmaceuticals Co. Ltd.

The MCP disease footprint includes Diabetes Mellitus, Type 2, Pseudotumor Cerebri. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03313297	Phase 2	Completed	28	Primary endpoint not disclosed in English source
NCT03111810	Phase 2	Completed	32	Primary endpoint not disclosed in English source
ISRCTN32813419	Phase 2	Completed	100	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

SAT277 Intracellular Cortisol Control: An Approach To Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk?

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: 24h urinary cortisol = 100.7 nmol ; 24h urinary cortisol = 89.6 nmol

Effect of AZD4017, a selective 11β-HSD1 inhibitor, on bone turnover markers in post-menopausal osteopenia.

Phase 2; n=55; evaluation: Not stated in English source. Reported fields: Osteocalcin = 22.3 ng/mL ; Osteocalcin = 21.7 ng/mL

Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial

Phase 2; n=28; evaluation: Positive. Reported fields: 11β-HSD1 activity(conversion): difference = 1.1(90% CI, -3.4 to 5.5); 11β-HSD1 activity(conversion): difference = 1.1(90% CI, -3.4 to 5.5)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

AZD-4017 addresses Diabetes Mellitus, Type 2, Pseudotumor Cerebri. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “target-level comparable: 11β-HSD1.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: 11β-HSD1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Automated assessment of wound tissue”. The milestone feed surfaced a patent-application signal described as “Compositions and uses thereof”. The milestone feed surfaced a patent-application signal described as “Treatment of sarcopenic diseases”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO